Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.
JAMA Netw Open. 2021 Aug 2;4(8):e2119600. doi: 10.1001/jamanetworkopen.2021.19600.
In the literature on opioid use disorder (OUD), opioid abstinence is used as an outcome measure for individuals receiving medication-assisted treatment (MAT), without consideration of patient-reported goals (PRGs).
To identify common PRGs for youths receiving MAT for OUD and assess whether these patients achieve their stated goals.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study examined data from 152 individuals aged 16 to 25 years (noninclusive) recruited between May 22, 2018, and March 11, 2020, from 45 outpatient MAT clinics in the Pharmacogenetics of Opioid Substitution Treatment Response study. Youths receiving MAT for OUD were included and were followed up for 3 months.
Medication-assisted treatment for OUD.
The frequency of each PRG; the success of goal attainment, compared between those who reported specific PRGs and those who did not; and associations between reporting certain goals and achieving them.
Among the 152 youths in the study, 82 were male (53.9%), and the mean (SD) age was 22.8 (1.8) years. Ten overarching goals were identified, with the most common being to taper the dose of or stop MAT (96 [63.2%]), avoid use of recreational substances (71 [46.7%]), manage OUD symptoms (25 [16.4%]), live a normal life (14 [9.2%]), improve mental health (11 [7.2%]), and gain employment (8 [5.3%]). Overall, individuals who reported PRGs had similar odds of achieving them as those who did not for the goals of taper dose of or stop MAT (OR, 1.98; 95% CI, 0.88-4.46; P = .10), avoid recreational substances (OR, 1.34; 95% CI, 0.65-2.74; P = .43), manage OUD symptoms (β coefficient, -0.93; 95% CI, -4.24 to 2.38; P = .58), and improve mental health (β coefficient, -0.76; 95% CI, -6.31 to 4.78; P = .79). Furthermore, multivariable logistic regression showed that goals to taper the dose of or stop MAT (odds ratio, 1.90; 95% CI, 0.78-4.63; P = .16) or avoid recreational substances (odds ratio, 1.27; 95% CI, 0.60-2.67; P = .53) were not associated with achieving these respective outcomes.
This study suggests that youths have highly variable PRGs regarding MAT for OUD and that reporting a goal may not mean one is at higher odds of achieving it. There is a need to develop treatment plans that effectively incorporate PRGs. In addition, the finding that most youths aim to minimize or stop their MAT dose warrants the creation of a tapering protocol to guide clinicians. Because a diagnosis of OUD has substantial psychosocial implications in this population, clinicians must ensure that these dimensions of care are part of routine clinical practice.
在阿片类药物使用障碍(OUD)的文献中,将接受药物辅助治疗(MAT)的个体的阿片类药物戒断作为结果测量指标,而没有考虑患者报告的目标(PRGs)。
确定接受 MAT 治疗 OUD 的年轻人的常见 PRGs,并评估这些患者是否实现了他们的既定目标。
设计、设置和参与者:这项前瞻性队列研究检查了 2018 年 5 月 22 日至 2020 年 3 月 11 日期间从 Pharmacogenetics of Opioid Substitution Treatment Response 研究中的 45 个门诊 MAT 诊所招募的 152 名年龄在 16 至 25 岁之间(不包括 16 岁和 25 岁)的个体的数据。包括接受 OUD MAT 的年轻人,并对他们进行了 3 个月的随访。
OUD 的 MAT。
每个 PRG 的频率;与未报告特定 PRG 的人相比,报告特定 PRG 的人实现目标的成功率;以及报告某些目标与实现这些目标之间的关联。
在这项研究的 152 名年轻人中,82 名是男性(53.9%),平均(SD)年龄为 22.8(1.8)岁。确定了 10 个总体目标,其中最常见的是减少或停止 MAT 的剂量(96 [63.2%])、避免使用娱乐性药物(71 [46.7%])、控制 OUD 症状(25 [16.4%])、过正常生活(14 [9.2%])、改善心理健康(11 [7.2%])和获得就业(8 [5.3%])。总体而言,与未报告 PRG 的人相比,报告 PRG 的人在达到 MAT 剂量减少或停止(OR,1.98;95%CI,0.88-4.46;P=0.10)、避免娱乐性药物(OR,1.34;95%CI,0.65-2.74;P=0.43)、控制 OUD 症状(β系数,-0.93;95%CI,-4.24 至 2.38;P=0.58)和改善心理健康(β系数,-0.76;95%CI,-6.31 至 4.78;P=0.79)的目标方面,具有相似的可能性。此外,多变量逻辑回归显示,减少或停止 MAT 剂量(优势比,1.90;95%CI,0.78-4.63;P=0.16)或避免娱乐性药物(优势比,1.27;95%CI,0.60-2.67;P=0.53)的目标与实现这些目标没有关联。
这项研究表明,年轻人对 OUD 的 MAT 有高度不同的 PRG,并且报告目标并不意味着他们实现目标的可能性更高。需要制定有效的治疗计划,将 PRGs 纳入其中。此外,大多数年轻人的目标是尽量减少或停止他们的 MAT 剂量,这需要制定一个减量方案来指导临床医生。由于 OUD 的诊断对该人群具有重大的心理社会影响,因此临床医生必须确保这些护理方面是常规临床实践的一部分。